Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-hydroxy-n-demethyltamoxifen
2. 4-hydroxy-n-desmethyltamoxifen
3. 4-hydroxy-n-desmethyltamoxifen, (z)-isomer
4. Z-endoxifen
1. 112093-28-4
2. Z-endoxifen
3. 4-hydroxy-n-desmethyltamoxifen
4. Endoxifen Z-isomer
5. N-desmethyl-4-hydroxytamoxifen
6. (z)-endoxifen
7. 110025-28-0
8. (z)-4-hydroxy-n-desmethyl Tamoxifen (mixture Of Isomers)
9. 4ohndtam
10. Nsc-749798
11. N-desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/z Mixture)
12. 4-hydroxy-n-desmethyl-tamoxifen
13. Chebi:80555
14. 46af8680rc
15. 4-[(z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
16. (z)-4-hydroxy-n-desmethyl Tamoxifen (contains Up To 10% E Isomer)
17. Unii-46af8680rc
18. 4-hydroxy-n-desmethyltamoxifen, (z)-isomer
19. 4-hydroxy-n-desmethyl Tamoxifen
20. (z)-4-(1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenylbut-1-en-1-yl)phenol
21. Endoxifenz-isomer
22. Phenol, 4-((1z)-1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenyl-1-buten-1-yl)-
23. Endoxifen(e/z=1:1)
24. Endoxifen [who-dd]
25. Chembl1093458
26. Schembl10107920
27. Gtpl10203
28. Dtxsid80149880
29. Ex-a645
30. Phenol, 4-[(1z)-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]-
31. Bcp15866
32. Ex-a1970
33. 4-[1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
34. Bdbm50435003
35. Hy-18719e
36. Nsc746494
37. Nsc749798
38. Nsc777380
39. Zinc22056306
40. Nsc 749798
41. Nsc-746494
42. Nsc-777380
43. Ncgc00386714-01
44. Ac-36810
45. Be172975
46. Bs-42369
47. B7481
48. Cs-0028594
49. (z)-4-hydroxy-n-desmethyl Tamoxifen (endoxifen)
50. A894656
51. N-desmethyl-4-hydroxytamoxifen, Mixture Of Isomers
52. 4-hydroxy-n-desmethyl Tamoxifen ((e/z)-endoxifen)
53. J-002363
54. W-200834
55. Q27149598
56. N-desmethyl-4-hydroxy Tamoxifen(approx. 1:1 E/z Mixture)
57. (z)-4-hydroxy-n-desmethyl Tamoxifen(contains Up To 10% E Isomer)
58. (e/z)-4-(1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol
59. (z)-4-(1-(4-(2-(methylamino)ethoxy)phenyl)-2-phenylbut-1-enyl)phenol
60. 4-[(~{z})-1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
61. N-desmethyl-4-hydroxytamoxifen, Mixture Of Isomers, Analytical Standard
62. (e/z)-4-[1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]-phenol
63. 4-[(1z)-1-{4-[2-(methylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl]phenol
64. N-methyl-2-[4-[(e)-1-(4-hydroxyphenyl)-2-phenyl-1-butenyl]phenoxy]ethanamine
65. Phenol, 4-(1-(4-(2-(methylamino)ethoxy]phenyl)-2-phenyl-1-butenyl)-, (z)-
| Molecular Weight | 373.5 g/mol |
|---|---|
| Molecular Formula | C25H27NO2 |
| XLogP3 | 6.3 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 8 |
| Exact Mass | 373.204179104 g/mol |
| Monoisotopic Mass | 373.204179104 g/mol |
| Topological Polar Surface Area | 41.5 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 467 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Endoxifen has known human metabolites that include Endoxifen O-glucuronide and Endoxifen O-sulfate.
Endoxifen is a known human metabolite of 4-Hydroxytamoxifen and N-Desmethyltamoxifen.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
Drugs in Development
Details:
(Z)-endoxifen is a highly potent Selective Estrogen Receptor Modulator (SERM) with demonstrated ability to inhibit—and potentially degrade—estrogen receptors.
Lead Product(s): Endoxifen,Inapplicable
Therapeutic Area: Oncology Brand Name: (Z)-Endoxifen
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 14, 2025
Atossa Reports Full I-SPY 2 Study Results on Low-Dose (Z)-Endoxifen
Details : (Z)-endoxifen is a highly potent Selective Estrogen Receptor Modulator (SERM) with demonstrated ability to inhibit—and potentially degrade—estrogen receptors.
Product Name : (Z)-Endoxifen
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 14, 2025
Details:
Endoxifen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Bipolar Disorder.
Lead Product(s): Endoxifen,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Novum Pharmaceutical Research Services
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 23, 2024
Lead Product(s) : Endoxifen,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Novum Pharmaceutical Research Services
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
Details : Endoxifen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Bipolar Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 23, 2024
Details:
Testosterone is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Intraductal, Noninfiltrating.
Lead Product(s): Testosterone,Anastrozole,Elacestrant,Endoxifen
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 10, 2023
Lead Product(s) : Testosterone,Anastrozole,Elacestrant,Endoxifen
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Testosterone is a Hormone drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Intraductal, Noninfiltrating.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
October 10, 2023
Details:
Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Lead Product(s): Endoxifen,Inapplicable
Therapeutic Area: Oncology Brand Name: (Z)-Endoxifen
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Quantum Leap Healthcare
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 28, 2023
Lead Product(s) : Endoxifen,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Quantum Leap Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Product Name : (Z)-Endoxifen
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 28, 2023
Details:
Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Lead Product(s): Endoxifen,Inapplicable
Therapeutic Area: Oncology Brand Name: (Z)-Endoxifen
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 12, 2023
Details : Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Product Name : (Z)-Endoxifen
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 12, 2023
Details:
Under the agreement, Societal CDMO will provide a range of its Clinical Trial Services offerings focused on Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, the most active metabolite of the FDA approved SERM, tamoxifen.
Lead Product(s): Endoxifen,Inapplicable
Therapeutic Area: Oncology Brand Name: (Z)-Endoxifen
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Atossa Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 23, 2023
Lead Product(s) : Endoxifen,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Atossa Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Societal CDMO will provide a range of its Clinical Trial Services offerings focused on Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, the most active metabolite of the FDA approved SERM, tamoxifen...
Product Name : (Z)-Endoxifen
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 23, 2023
Details:
(Z)-endoxifen is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Lead Product(s): Endoxifen,Inapplicable
Therapeutic Area: Oncology Brand Name: (Z)-Endoxifen
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Quantum Leap Healthcare
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 21, 2023
Lead Product(s) : Endoxifen,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Quantum Leap Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : (Z)-endoxifen is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.
Product Name : (Z)-Endoxifen
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 21, 2023
Details:
(Z)-Endoxifen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): Endoxifen,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: InClin
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 07, 2022
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Details : (Z)-Endoxifen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 07, 2022
Details:
Endoxifen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Lead Product(s): Endoxifen,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 05, 2021
Lead Product(s) : Endoxifen,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density
Details : Endoxifen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 05, 2021
Details:
Endoxifen, an active metabolite of tamoxifen, which is an FDA-approved drug to treat ovarian and breast cancer. Endoxifen administered to breast cancer patients prior to surgery.
Lead Product(s): Endoxifen,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 07, 2021
Atossa Therapeutics Shares Jump 35% Ahead of Data on Endoxifen in Breast Cancer Surgery Patients
Details : Endoxifen, an active metabolite of tamoxifen, which is an FDA-approved drug to treat ovarian and breast cancer. Endoxifen administered to breast cancer patients prior to surgery.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 07, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
88
PharmaCompass offers a list of Endoxifen API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Endoxifen manufacturer or Endoxifen supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Endoxifen manufacturer or Endoxifen supplier.
PharmaCompass also assists you with knowing the Endoxifen API Price utilized in the formulation of products. Endoxifen API Price is not always fixed or binding as the Endoxifen Price is obtained through a variety of data sources. The Endoxifen Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Endoxifen manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Endoxifen, including repackagers and relabelers. The FDA regulates Endoxifen manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Endoxifen API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Endoxifen supplier is an individual or a company that provides Endoxifen active pharmaceutical ingredient (API) or Endoxifen finished formulations upon request. The Endoxifen suppliers may include Endoxifen API manufacturers, exporters, distributors and traders.
Endoxifen Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Endoxifen GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Endoxifen GMP manufacturer or Endoxifen GMP API supplier for your needs.
A Endoxifen CoA (Certificate of Analysis) is a formal document that attests to Endoxifen's compliance with Endoxifen specifications and serves as a tool for batch-level quality control.
Endoxifen CoA mostly includes findings from lab analyses of a specific batch. For each Endoxifen CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Endoxifen may be tested according to a variety of international standards, such as European Pharmacopoeia (Endoxifen EP), Endoxifen JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Endoxifen USP).
